Alvogen
Alvogen is a privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world.
The US-based company has commercial operations in 35 countries with 2,300 employees and operates four manufacturing and development hubs in the US, Romania, Korea and Taiwan. North America is Alvogen’s single largest market and other key markets include: South Korea, West Balkan, Poland, Romania, Bulgaria, Hungary, Taiwan, Thailand, Ukraine, Russia, Japan and China.
North America is the company's largest market with more than 60 pending Abbreviated New Drug Application (ANDA) filings.
Latest Alvogen News & Features
25 May 2022
18 September 2020
25 November 2019
25 October 2019
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze